No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and will be paid out over a multi-year period. Settlement will not change BD's cash flow goals or capital allocation strategy. FRANKLIN LAKES, N.J., Oct. 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has reached an agreement to ...

FRANKLIN LAKES, N.J., Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operating room. New data highlights how advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operati ...

LE PONT-DE-CLAIX, France, Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies. BD announces the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Ne ...

Company Overview - Becton, Dickinson and Company (BDX) is a medical technology company based in Franklin Lakes, NJ, primarily engaged in the development, manufacture, and sale of medical devices, instrument systems, and reagents [10]. Investment Ratings - BDX currently holds a Zacks Rank of 3 (Hold) with a VGM Score of B, indicating a moderate investment outlook [10]. - The company is considered a potential top pick for growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 7.3% for the current fiscal year [11]. Earnings Estimates - In the last 60 days, 10 analysts have revised their earnings estimates higher for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.06 to $13.10 per share [11]. - BDX has an average earnings surprise of 6.2%, suggesting that the company has a history of exceeding earnings expectations [11].

Becton, Dickinson, and Company (BDX) , popularly known as BD, completed its acquisition of Edwards Lifesciences Corporation (EW) Critical Care product group, renaming it BD Advanced Patient Monitoring. BD had announced a $4.2 billion deal to acquire Edwards Lifesciences' Critical Care product group in June. The acquisition strengthens BD's portfolio of advanced monitoring solutions with AI-enabled clinical decision tools. The acquired business also has a strong innovation pipeline that is poised to drive in ...

Becton, Dickinson and Company (NYSE:BDX) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning. I'm Larry Biegelsen, the MedTech Analyst at Wells Fargo. And it's my pleasure to host this session with the management team from Becton, Dickinson. With us, we have Tom Polen, Chairman, President and CEO; and Adam Reiffe, sorry, should ...

Becton, Dickinson and Company (NYSE:BDX) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning. I'm Larry Biegelsen, the MedTech Analyst at Wells Fargo. And it's my pleasure to host this session with the management team from Becton, Dickinson. With us, we have Tom Polen, Chairman, President and CEO; and Adam Reiffe, sorry, should ...

Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities Business renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segment Katie Szyman will continue to ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Develop ...

Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J., Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its manufacturing operations in Columbus, Neb., and reinforced the need for and value of domestic production for critical medical devices. BD first opened its doors in Columbus, Nebraska in 1949 with 15 employees in this 25,000 sq. ft. facility, manufacturin ...